Intellipharmaceutics International Inc. (IPCIQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Mar 19, 2025
IPCIQ Income Statement
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '23 Aug 31, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | Nov '19 Nov 30, 2019 | Nov '18 Nov 30, 2018 | 2013 - 2017 |
| Revenue | 0.9 | 0.07 | - | 1.4 | 3.48 | 1.71 | Upgrade
|
| Revenue Growth (YoY) | 2410.53% | - | - | -59.73% | 103.21% | -68.88% | Upgrade
|
| Cost of Revenue | 0.48 | - | - | - | 0.03 | 0.12 | Upgrade
|
| Gross Profit | 0.43 | 0.07 | - | 1.4 | 3.45 | 1.59 | Upgrade
|
| Selling, General & Admin | 0.77 | 0.56 | 1.28 | 2.15 | 4.17 | 3.48 | Upgrade
|
| Research & Development | 2.06 | 2.15 | 2.66 | 3.52 | 6.61 | 10.83 | Upgrade
|
| Operating Expenses | 3.01 | 2.92 | 4.21 | 6.08 | 11.28 | 14.91 | Upgrade
|
| Operating Income | -2.58 | -2.85 | -4.21 | -4.68 | -7.83 | -13.33 | Upgrade
|
| Interest Expense | -0.23 | -0.29 | -0.55 | -0.97 | -0.25 | -0.26 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.01 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.1 | 0.21 | -0.02 | -0.17 | -0.03 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | -2.71 | -2.93 | -4.78 | -5.82 | -8.09 | -13.75 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.46 | 0.04 | - | -0.04 | - | - | Upgrade
|
| Asset Writedown | - | - | -0.51 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | 2.5 | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.03 | - | 0 | - | Upgrade
|
| Pretax Income | -3.17 | -2.89 | -5.26 | -3.36 | -8.09 | -13.75 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | -0.11 | 0.03 | -0.01 | - | Upgrade
|
| Net Income | -3.17 | -2.89 | -5.15 | -3.39 | -8.08 | -13.75 | Upgrade
|
| Net Income to Common | -3.17 | -2.89 | -5.15 | -3.39 | -8.08 | -13.75 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 33 | 29 | 24 | 22 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 33 | 29 | 24 | 22 | 5 | Upgrade
|
| Shares Change (YoY) | 24.88% | 12.45% | 24.91% | 9.18% | 353.15% | 53.55% | Upgrade
|
| EPS (Basic) | -0.09 | -0.09 | -0.17 | -0.14 | -0.37 | -2.89 | Upgrade
|
| EPS (Diluted) | -0.09 | -0.09 | -0.17 | -0.14 | -0.37 | -2.89 | Upgrade
|
| Free Cash Flow | 0.12 | -1.39 | -2.46 | 0.11 | -6.68 | -12.61 | Upgrade
|
| Free Cash Flow Per Share | 0.00 | -0.04 | -0.08 | 0.01 | -0.31 | -2.65 | Upgrade
|
| Gross Margin | 47.41% | 100.00% | - | 100.00% | 99.05% | 92.71% | Upgrade
|
| Operating Margin | -285.07% | -4336.82% | - | -333.80% | -225.11% | -778.07% | Upgrade
|
| Profit Margin | -350.72% | -4400.55% | - | -241.95% | -232.28% | -802.66% | Upgrade
|
| Free Cash Flow Margin | 13.31% | -2112.07% | - | 7.72% | -191.87% | -736.26% | Upgrade
|
| EBITDA | -2.41 | -2.65 | -3.95 | -4.26 | -7.33 | -12.71 | Upgrade
|
| EBITDA Margin | -266.03% | - | - | - | -210.55% | - | Upgrade
|
| D&A For EBITDA | 0.17 | 0.21 | 0.26 | 0.42 | 0.51 | 0.61 | Upgrade
|
| EBIT | -2.58 | -2.85 | -4.21 | -4.68 | -7.83 | -13.33 | Upgrade
|
| EBIT Margin | -285.07% | - | - | - | -225.11% | - | Upgrade
|
| Revenue as Reported | 0.07 | 0.07 | - | 1.4 | 3.48 | 1.71 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.